Plain-English translation of NCT05353140 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a small implanted heart device called the WATCHMAN can work as well as daily blood thinner medication (rivaroxaban) for preventing strokes and blood clots in patients with atrial fibrillation who have also had a stent placed in their heart. The device is a tiny umbrella-like implant that closes off a small pouch in the heart where clots can form, while the medication works by thinning your blood to prevent clots.
Many patients with irregular heartbeat who also need a heart stent must take multiple blood-thinning medications, which significantly increases their bleeding risk. This trial is looking for a safer option that could reduce dangerous bleeding complications while still protecting against strokes.
You likely qualify if…
You likely don't qualify if…
If you are randomly assigned to the device group, you will undergo a minor procedure to have the WATCHMAN device implanted in your heart, followed by specific medication schedules for about a year. If assigned to the medication group, you will take a daily blood thinner (rivaroxaban) plus another medication (clopidogrel) for one year. Both groups will have regular follow-up visits to monitor your health and check for any bleeding or clotting complications.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
China